Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06112704 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 2, 2024 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study Identification, Study Status, Oversight, Contacts/Locationsv5
  2. Study sites: 1 to 21v4
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jan 31, 2024 to Feb 6, 2024v3 Show 1 more changeShow less
    • Start date changed from estimate of Jan 31, 2024 to Feb 6, 2024
  4. Study title shortened, about 4 wordsv2 See this version in full on ClinicalTrials.gov ↗
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the anti-tumor activity, safety, pharmacokinetics and immunogenicity of HS-20093 in Chinese advanced esophageal carcinoma and other solid tumor patients.
Trial Details
NCT Number NCT06112704
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Advanced Solid Tumor
Enrollment 220 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov